Cerebral ischemia initiates a cascade of events that can lead to secondary neuronal damage resulting in an increased extent of infarct and poorer clinical outcome. The restoration of blood flow to the area surrounding the infarct, although essential for patient recovery, elicits an inflammatory response that plays a significant role in secondary injury. The complement system plays a key role in the pathophysiology of many inflammatory and ischemic diseases, and clinical studies and interventional studies in experimental models indicate an important role for complement in neuronal injury following ischemic stroke. The long term goal of this project is to gain a better understanding of complement-dependent mechanisms involved in the pathogenesis of ischemic stroke, and to develop an efficacious and safe neuroprotective strategy based on attenuating complement-dependent injury. We will characterize the effects of various novel complement inhibitors that target either complement activation products or selectins. The role and relative contributions of P and E selectin in the context of complement activation will be investigated by the use of selectin targeting moieties with function blocking activity. The targeting strategies have been validated in other models of inflammation and ischemia and reperfusion injury, and we have shown that appropriate targeting of complement inhibitors not only markedly increases their bioavailability and efficacy, but obviates the need to systemically inhibit complement. Systemic complement inhibition and immunosupression is a potential concern with regard to the treatment of stroke patients, since infectious complications occur in a high proportion of patients within the first few days after stroke. The targeted complement inhibitors will be characterized in a murine model of transient focal cerebral ischemia. In addition to therapeutic determinations, we will elucidate pathophysiological mechanisms by investigating the roles and contributions of each selectin and different complement activation products in cerebral ischemia and reperfusion injury. To this end, we will determine in vivo relationships between neuronal injury, functional recovery, local and systemic complement inhibition, the generation of different complement activation products, P vs. E selectin antagonisms with and without complement inhibition, cytokine production, adhesion molecule expression, leukocyte infiltration and activation, and platelet adhesion and aggregation.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL082485-04
Application #
7536413
Study Section
Special Emphasis Panel (ZHL1-CSR-H (O1))
Program Officer
Kindzelski, Andrei L
Project Start
2005-12-01
Project End
2010-11-30
Budget Start
2008-12-01
Budget End
2009-11-30
Support Year
4
Fiscal Year
2009
Total Cost
$318,974
Indirect Cost
Name
Medical University of South Carolina
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Liu, Fengming; Wu, Lin; Wu, Gongxiong et al. (2014) Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice. Atherosclerosis 234:237-43
Marshall, Keely M; He, Songqing; Zhong, Zhi et al. (2014) Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy. J Exp Med 211:1793-805
Holers, V Michael; Rohrer, Bärbel; Tomlinson, Stephen (2013) CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol 735:137-54
Atkinson, Carl; Floerchinger, Bernhard; Qiao, Fei et al. (2013) Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts. Circulation 127:1290-9
Ramos, Theresa N; Darley, Meghan M; Weckbach, Sebastian et al. (2012) The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria. J Biol Chem 287:24734-8
Elvington, Andrew; Atkinson, Carl; Kulik, Liudmila et al. (2012) Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol 188:1460-8
Hu, Xianzhen; Tomlinson, Stephen; Barnum, Scott R (2012) Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE. Neurosci Lett 531:35-9
Elvington, Andrew; Atkinson, Carl; Zhu, Hong et al. (2012) The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J Immunol 189:4640-7
Qing, Xiaoping; Redecha, Patricia B; Burmeister, Melissa A et al. (2011) Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int 79:331-9
Sekine, Hideharu; Kinser, Ting Ting Hsieh; Qiao, Fei et al. (2011) The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 63:1076-85

Showing the most recent 10 out of 16 publications